A comprehensive map of molecular drug targets

Nature Reviews Drug Discovery

Volumn 16, Issue 1, 2016, Pages 19-34

  Santos, Rita ^a,b   Ursu, Oleg ^c   Gaulton, Anna ^a   Bento, A Patrícia ^a   Donadi, Ramesh S ^a   Bologa, Cristian G ^c   Karlsson, Anneli ^a,d   Al Lazikani, Bissan ^e   Hersey, Anne ^a   Oprea, Tudor I ^c   Overington, John P ^a,d  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d BenevolentAI   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PRODRUG;

ARTICLE; CANCER THERAPY; DISEASE MODEL; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGET MOLECULAR MAPPING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENETIC VARIATION; GENOME; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; ORTHOLOGY; PRESCRIPTION; PRIORITY JOURNAL; DRUG APPROVAL; DRUG DATABASE; DRUG DELIVERY SYSTEM; HUMAN GENOME; PHARMACOGENETICS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

DATABASES, PHARMACEUTICAL; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG PRESCRIPTIONS; GENETIC VARIATION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85000936652     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.230     Document Type: Article

References (62)

1. Raju T. N. The Nobel chronicles. Lancet 355, 1022 (2000).
2. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14, 1516-1518 (1996).
3. Drews J, & Ryser S. Classic drug targets. Nat. Biotechnol. 15, 1350 (1997).
4. Hopkins A. L, & Groom C. R. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
5. Golden J. B. Prioritizing the human genome: knowledge management for drug discovery. Curr. Opin. Drug Discov. Devel. 6, 310-316 (2003).
6. Imming P, Sinning C, & Meyer A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-835 (2006).
7. Overington J. P, Al Lazikani B, & Hopkins A. L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
8. Chen X, Ji Z. L, & Chen Y. Z. TTD: Therapeutic Target Database. Nucleic Acids Res. 30, 412-415 (2002).
9. Wishart D. S, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672 (2006).
10. Günther S, et al. SuperTarget and Matador: resources for exploring drug-Target relationships. Nucleic Acids Res. 36, D919-D922 (2008).
11. Rask-Andersen M, Almén M. S, & Schiöth H. B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590 (2011).
12. Munos B. A. Forensic analysis of drug targets from 2000 through 2012. Clin. Pharmacol. Ther. 94, 407-411 (2013).
13. Agarwal P, Sanseau P, & Cardon L. R. Novelty in the target landscape of the pharmaceutical industry. Nat. Rev. Drug Discov. 12, 575-576 (2013).
14. Pawson A. J, et al. The IUPHAR/BPS Guide to pharmacology: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 42, D1098-D1106 (2014).
15. Ursu O, et al. DrugCentral: online drug compendium. Nucleic Acids Res. doi: 10.1093/nar/gkw993 (2016).
16. Tym J. E, et al. canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 44, D938-D943 (2016).
17. Bento A. P, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 42, D1083-D1090 (2014).
18. Meltzer H. Y, & Roth B. L. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-Targeted drugs. J. Clin. Invest. 123, 4986-4991 (2013).
19. Friedman J. H. Pimavanserin for the treatment of Parkinson?s disease psychosis. Expert Opin. Pharmacother. 14, 1969-1975 (2013).
20. Bandelow B, & Meier A. Aripiprazole, a ?dopamine-serotonin system stabilizer? in the treatment of psychosis. German J. Psychiatry 6, 9-16 (2003).
21. Mamo D, et al. Differential effects of aripiprazole on D2, 5 HT2, and 5 HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 164, 1411-1417 (2007).
22. Tolboom N, et al. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [11C]raclopride PET study in healthy human subjects. Neuropsychopharmacology 40, 472-479 (2015).
23. Rang H. P, Dale M. M, Ritter J. M, Flower R. J, & Henderson G. (eds) Rang and Dale?s Pharmacology 7th edn (Elsevier Health Sciences UK, 2012).
24. Koarai A, et al. Expression of muscarinic receptors by human macrophages. Eur. Respir. J. 39, 698-704 (2012).
25. Lammers J. W, Minette P, McCusker M, & Barnes P. J. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am. Rev. Respir. Dis. 139, 446-449 (1989).
26. Krauss J, van der Linden M, Grebe T, & Hakenbeck R. Penicillin-binding proteins 2x and 2b as primary PBP targets in Streptococcus pneumoniae. Microb. Drug Resist. 2, 183-186 (1996).
27. Wells S. A, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase iii trial. J. Clin. Oncol. 30, 134-141 (2012).
28. Santoro M, et al. Molecular biology of the MEN2 gene. J. Intern. Med. 243, 505-508 (1998).
29. Thollon C, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br. J. Pharmacol. 150, 37-46 (2007).
30. Sobrado L. F, et al. Dronedarone?s inhibition of If current is the primary mechanism responsible for its bradycardic effect. J. Cardiovasc. Electrophysiol. 24, 914-918 (2013).
31. Bucchi A, et al. Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS ONE 8, e53132 (2013).
32. Xynogalos P, et al. Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224. Naunyn. Schmiedebergs. Arch. Pharmacol. 387, 1153-1161 (2014).
33. Gómez R, et al. Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. Cardiovasc. Res. 104, 337-346 (2014).
34. Heijman J, Heusch G, & Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin. Med. Insights Cardiol. 7, 127-140 (2013).
35. Brayfield A. Martindale: The Complete Drug Reference 38th edn (Pharmaceutical Press, 2014).
36. Swiss Pharmaceutical Society. Index Nominum: International Drug Directory 18th edn (Medpharm Scientific Publishers, 2004).
37. Allen T. M. Ligand-Targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763 (2002).
38. International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010).
39. Kandoth C, et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
40. Vogelstein B, et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
41. Lawrence M. S, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
42. Soda M, et al. Identification of the transforming EML4 ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
43. Workman P, & Al Lazikani B. Drugging cancer genomes. Nat. Rev. Drug Discov. 12, 889-890 (2013).
44. Fletcher J. I, Haber M, Henderson M. J, & Norris M. D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10, 147-156 (2010).
45. Patel M. N, Halling-Brown M. D, Tym J. E, Workman P, & Al Lazikani B. Objective assessment of cancer genes for drug discovery. Nat. Rev. Drug Discov. 12, 35-50 (2013).
46. Luo J, Solimini N. L, & Elledge S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
47. Weinstein I. B, & Joe A. Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
48. Matteo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer N. Engl. J. Med. 373, 1697-1708 (2015).
49. Shukla N. Proteasome addiction defined in Ewing sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors Cancer Res. 76, 4525-4534 (2016).
50. Eder J, Sedrani R, & Wiesmann C. The discovery of first in class drugs: origins and evolution. Nat. Rev. Drug Discov. 13, 577-587 (2014).
51. Swinney D. C, & Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519 (2011).
52. Al Lazikani B, & Workman P. Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer Discov. 3, 14-19 (2013).
53. Workman P, Clarke P. A, & Al Lazikani B. Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget 7, 3658-3661 (2016).
54. Paolini G. V, Shapland R. H. B, van Hoorn W. P, Mason J. S, & Hopkins A. L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006).
55. Huttunen K. M, Raunio H, & Rautio J. Prodrugs-from serendipity to rational design. Pharmacol. Rev. 63, 750-771 (2011).
56. Huang R, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl Med. 3, 80ps16 (2011).
57. Kinsella R. J, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database 2011, bar030 (2011).
58. Flicek P, et al. Ensembl 2012. Nucleic Acids Res. 40, D84-D90 (2012).
59. Sonnhammer E. L. L, & Östlund G. InParanoid 8: orthology analysis between 273 proteomes, mostly eukaryotic. Nucleic Acids Res. 43, D234-D239 (2015).
60. United States Pharmacopeial Convention. USP Dictionary of USAN and International Drug Names 2010 (United States Pharmacopeia, 2010).
61. Gleeson M. P, Hersey A, Montanari D, & Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197-208 (2011).
62. Krzywinski M, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).